Exploratory data analyses of a drug-biomarker efficacy PD model

This webinar walks through a real-world exploratory analysis of a PK/PD model where a drug inhibits a biomarker (its primary target), and that biomarker in turn inhibits clinical efficacy — two sequential inhibitory steps that together drive efficacy back toward baseline. You’ll see how initial parameter estimates are derived from biomarker and efficacy time-course data, and how a new in vivo potency expression captures the underlying target-binding and turnover dynamics more completely than a single potency parameter.

• How to derive initial parameter estimates from paired biomarker and efficacy time-course data for a sequential-inhibition PD model.
• How drug-target binding (kon/koff), target turnover (R0, kdeg), and complex elimination (ke(RC)) combine into a new expression for in vivo potency.
• How to replace a single potency parameter with a mechanistic expression that better reflects target engagement.
• How equilibrium expressions describe target inhibition and efficacy build-up as functions of drug concentration.
• Why this generic double-inhibition framework applies broadly to any system with two sequential negative (inhibitory) actions.